Boehringer Ingelheim partners with AnGes to develop HGF gene therapy for peripheral arterial disease, following AnGes' clinical trial completion. AnGes plans to submit a Biologics License Application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results